Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma

Multiple gene-driven programmed cell death 1 ligand 1 (PD-L1)-expressing non-small-cell lung cancer (NSCLC) is very rare. Previous studies have shown that patients with NSCLC with anaplastic lymphoma kinase (ALK) gene rearrangement rarely benefit from PD-L1 inhibitors. Besides the secondary mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Wen, Lei, Pengfei, Liu, Xin, Li, Qin, Cheng, Xiangyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600068/
https://www.ncbi.nlm.nih.gov/pubmed/34804000
http://dx.doi.org/10.3389/fimmu.2021.686057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600068/
https://www.ncbi.nlm.nih.gov/pubmed/34804000
http://dx.doi.org/10.3389/fimmu.2021.686057

Ejemplares similares